Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=cagrilintide,retatrutide,pramlintide

Side-by-side comparison of Cagrilintide, Retatrutide, Pramlintide
CagrilintideRetatrutidePramlintide
Identity
ClassInvestigational long-acting acylated amylin analogueInvestigational triple agonist of GIP, GLP-1 and glucagon receptorsAmylin analogue
Also listed asNot recordedLY3437943, LY-3437943Symlin, AC-137
Molecular formulaC194H312N54O59S2Not recordedC171H267N51O53S2
Molecular weight4409 g/mol4731.33 g/mol (average mass, widely cited for the free base)3949 g/mol
CAS1415456-99-32381089-83-2151126-32-8
PubChem CID171397054Not recorded70691388
Sequence lengthDescribed structurally, not as a residue listNot recordedDescribed structurally, not as a residue list
Data caveatNone recordedPubChem’s retatrutide record states a CID is not available as a discrete structure. Full caveatNone recorded
United States regulatory status
StatusInvestigationalInvestigationalFormerly approved — discontinued
FDA applicationNone recordedNone recordedNDA 021332 (SYMLIN) — every product listed as discontinued
CompoundingNo FDA compounding entry recordedNo FDA compounding entry recordedNo FDA compounding entry recorded
WADANot named in this recordNot named in this recordNot named in this record
Research profile
Research purposeNo plain-English profile recordedTriple-agonist metabolic researchNo plain-English profile recorded
Proposed mechanismNo plain-English profile recordedProposed triple agonism: GLP-1 and GIP effects on appetite and insulin, plus glucagon-receptor signalling in the liver and energy expenditure. The net clinical contribution of each arm is still being studied.No plain-English profile recorded
Human evidenceNo plain-English profile recordedA published 48-week Phase 2 trial in 338 adults, plus Phase 3 trials registered and sponsor topline disclosures. No approved product exists.No plain-English profile recorded
Evidence tierNo plain-English profile recordedPhase 3 trials registered or reportedNo plain-English profile recorded
Known safety concernsNo plain-English profile recorded
  • Gastrointestinal adverse effects were reported in the Phase 2 trial.
  • Resting heart rate increased transiently in the Phase 2 trial.
  • The full Phase 3 safety database and any regulatory review are not public as an approved label.
No plain-English profile recorded
Evidence gapsNo plain-English profile recorded
  • Peer-reviewed Phase 3 results, including full adverse-event tables.
  • Long-term cardiovascular and lean-mass outcomes.
  • Any regulatory decision.
No plain-English profile recorded
Head-to-head evidenceNo plain-English profile recordedNo published head-to-head trial against semaglutide or tirzepatide. Cross-trial comparisons are not head-to-head evidence.No plain-English profile recorded
Named pathwaysNo plain-English profile recordedGIP receptor · GLP-1 receptor · Glucagon receptor · Hepatic lipid oxidation · Energy expenditureNo plain-English profile recorded
Evidence on file
Records
Human-interventional records020
Human-observational records000
Animal records000
In-vitro records000
Reviews000
Regulatory documents000
Earliest indexedNot recorded2023Not recorded
Latest indexedNot recorded2026Not recorded

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.